Current reports
Current report 38/2021 – Receipt of a notification regarding a change in the total number of votes in the Company
The Management Board of Celon Pharma S.A. informs that it has received the following notification from Mr. Maciej Wieczorek on a change in the total number of votes in the Company:
Current Report 37/2021 – Registration of share capital increase and amendments to the Company’s Articles of Association
Management Board of Celon Pharma S.A. (“Company”) informs that on September 9, 2021 the Regional Court for the Capital City of Warsaw in Warsaw, 14th Commercial Division of the National Court Register (the “Court”) registered the increase of the Company’s share capital as a result of the issuance of D-series shares within the authorized capital, conducted on the basis of the Resolution No. 4/2021 February 16, 2021 and the resolution of the Management Board of the Company of June 25, 2021. (current reports 9/2021 and 29/2021).
Current Report 36/2021 – Successful completion of Phase I clinical trial of the CPL’116 compound, the world’s first dual JAK/ROCK inhibitor
In connection with current report 6/2021 on completing a Phase IA clinical trial of an innovative JAK/ROCK kinase inhibitor (CPL’116) with potential therapeutic efficacy in autoimmune diseases, the Company wishes to announce that on 08/09/2021 it received information on the completion of the administration of the studied compound CPL’116 to healthy volunteers in Phase IB clinical trial. This means the completion of the Phase I clinical trial for the compound.
Current report 35/2021 – Summary of subscription of ordinary D-series bearer shares in Celon Pharma S.A.
Management Board of Celon Pharma S.A. _”The Company”_ provides information regarding the completed subscription nominal value of PLN 0.1 each. nominal value of PLN 0.1 each. _”Offered Shares”_ held pursuant to Resolution No. 4 of the Extraordinary General Meeting of the Company of February 16, 2021 _current report 9/2021_ and the resolution on the share capital increase under the authorized capital adopted by the Management Board of the Company on May 10, 2021. _current report 22/2021_, as amended by a resolution of the Management Board of the Company of May 25, 2021. _current report 29/2021_:
Current report 34/2021 – Allocation of D-series shares
Allocation of D-series shares
Current report 33/2021 – List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company held on June 29, 2021
List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company held on June 29, 2021
Current report 32/2021 – Resolutions adopted by the Annual General Meeting of Celon Pharma S.A. on June 29, 2021
Resolutions adopted by the Annual General Meeting of Celon Pharma S.A. on June 29, 2021
Current report 31/2021 – Resolution of the Annual General Meeting on the payment of the dividend
Resolution of the Annual General Meeting on the payment of the dividend
Current report 30/2021 – Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 29, 2021
Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 29, 2021